当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Clinical, Imaging and Pathological Characteristics of Brain Implanted Polylactic Co-Glycolic Acid Polymers Conjugated with Temozolomide

Jill Hicks, Simon Platt R, Shannon Holmes P, Elizabeth Howerth, Allison Haley, Jared Kaplan M and Edward Kaplan J

Definitive treatments for primary brain tumours are still sought. Slow- release local chemotherapy may provide a good effect and poly (lactide-co-glycolide) (PLGA) micro cylinders could allow this. We evaluated the neurological and histopathological consequences, and MRI visibility, of PLGA micro cylinders conjugated with Temozolomide and gadolinium implanted in normal canine brains. Eight purpose-bred beagles had cerebral implantation of micro cylinders combined with Temozolomide and gadolinium. MRI was performed following implantation and 28d later prior to necropsy and brain histopathology. All adverse events were associated with implantation and resolved. Dogs with six micro cylinders at 0 and 6.25% gadolinium had mild inflammation and all other dogs had greater brain inflammation, which increased with higher gadolinium concentrations and micro cylinder number. Micro cylinders with gadolinium were identifiable on MRI. Brain implantation of PLGA micro cylinders conjugated with gadolinium and Temozolomide is tolerated in healthy beagles. The lowest gadolinium percentage and micro cylinder number should be used if this therapy is pursued